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http://www.biomedcentral.com/1471-2296/13/100RESEARCH ARTICLE Open AccessProstate specific antigen testing policy worldwide
varies greatly and seems not to be in accordance
with guidelines: a systematic review
Saskia Van der Meer1, Sabine AM Löwik2, Willem H Hirdes1, Rien M Nijman3, Klaas Van der Meer2,
Josette EHM Hoekstra-Weebers4 and Marco H Blanker2*Abstract
Background: Prostate specific antigen (PSA) testing is widely used, but guidelines on follow-up are unclear.
Methods: We performed a systematic review of the literature to determine follow-up policy after PSA testing by
general practitioners (GPs) and non-urologic hospitalists, the use of a cut-off value for this policy, the reasons for
repeating a PSA test after an initial normal result, the existence of a general cut-off value below which a PSA result
is considered normal, and the time frame for repeating a test.
Data sources. MEDLINE, Embase, PsychInfo and the Cochrane library from January 1950 until May 2011.
Study eligibility criteria. Studies describing follow-up policy by GPs or non-urologic hospitalists after a primary PSA
test, excluding urologists and patients with prostate cancer. Studies written in Dutch, English, French, German, Italian
or Spanish were included. Excluded were studies describing follow-up policy by urologists and follow-up of patients
with prostate cancer. The quality of each study was structurally assessed.
Results: Fifteen articles met the inclusion criteria. Three studies were of high quality. Follow-up differed greatly both
after a normal and an abnormal PSA test result. Only one study described the reasons for not performing follow-up
after an abnormal PSA result.
Conclusions: Based on the available literature, we cannot adequately assess physicians’ follow-up policy after a
primary PSA test. Follow-up after a normal or raised PSA test by GPs and non-urologic hospitalists seems to a large
extent not in accordance with the guidelines.
Keywords: Prostate specific antigen, PSA, Follow-up, General practitioners, Non-urologic hospitalists, Guidelines,
Systematic reviewBackground
Recently, Vedel et al. showed that although most guide-
lines are cautious about screening for prostate cancer,
using PSA tests is routine practice in a variety of health-
care systems, both in North America and Europe [1].
The effect of prostate cancer screening on mortality
and quality of life remains unclear [2]. Even after the
European Randomised Study of Screening for Prostate
Cancer (ERSPC)- the only study that showed a clear* Correspondence: blanker@belvederelaan.nl
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distribution, and reproduction in any mediumpositive effect on prostate specific mortality - it is un-
known which patients may benefit from screen-detected
early diagnosis [3]. Still, Prostate Specific Antigen (PSA)
tests are used regularly in patients with and without
lower urinary tract symptoms (LUTS) [4-6].
The PSA test has several limitations: Due to its low
specificity, an elevated PSA level does not necessarily
indicate the presence of prostate cancer, as it can also
be caused by benign prostate hyperplasia (BPH), urinary
retention or prostatitis. Furthermore, test sensitivity at
the applied normal values is suboptimal: a normal PSA
value does not rule out prostate cancer [7,8]. Also, an ab-
normal PSA test result can have a great impact on a
patients’ mental health [9].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the PSA test have been developed. The American Uro-
logical Association (AUA) PSA Best Practice Statement
Update 2009 recommends to start regular screening for
prostate cancer at the age of 40 years in patients with
an anticipated lifespan of more than 10 years [9]. They
no longer mention a threshold value of PSA to prompt
follow-up, but advise basing the decision primarily on
PSA and Digital Rectal Examination (DRE) results. Also,
free and total PSA, patient’s age, PSA velocity, PSA
density, family history, ethnicity, prior biopsy history
and comorbidities need to be taken into account [9]. The
European Association of Urology (EAU) recommends
follow-up after an abnormal DRE or elevated serum PSA
measurement, with a cut-off level of <2.5-3 ng/ml for
younger men [10]. The European Society for Medical
Oncology does not recommend screening for prostate
cancer. However, they do advise prostate biopsies after
an abnormal DRE or elevated PSA values, although no
PSA cut-off value is mentioned [11].
It is unclear whether (and how) physicians use these
guidelines and what cut-off values are being considered
in daily practice. Especially follow-up by non-urologists
is not clearly described in the literature. We conducted a
systematic review of the literature on how follow-up after
PSA testing is being conducted. We focused on the fol-
lowing questions. What is the policy of general prac-
titioners (GPs) and non-urologic hospitalists after an
abnormal PSA test result and can a cut-off value be
determined for this policy? What are the reasons for
repeating a PSA test after an initial normal result, what
is the cut-off value used for a normal PSA test result and
what is the time frame for repeating the test?
Methods
Identification and selection of the literature
In November 2009, a search of the literature was per-
formed in duplicate (SM and SAML) to identify relevant
publications on follow-up by GPs and non-urologic hos-
pitalists after a PSA test. We used MEDLINE, Embase,
PsycInfo and the Cochrane library to search for articles
published from 1950 until October 2009. This search was
updated in May 2011. The terms general practitioner and
non-urologic hospitalist were linked by the Boolean oper-
ator OR. The Boolean operator AND linked these terms
to the term PSA and to the terms follow-up or referral or
consultation. For all these keywords one or more syno-
nyms were used and all items were searched using “All
fields” (Additional file 1: Appendix 1).
We included studies if the following criteria were met:
study contained original data, it described actions under-
taken by GPs or non-urologic specialists following an ini-
tial PSA test (no action, repeat the test, or referral to a
urologist), and the article was written in Dutch, English,French, German, Italian or Spanish. Excluded were stud-
ies describing actions undertaken by urologists and stud-
ies on patients with prostate cancer. Titles and abstracts
of the identified studies were checked and the full text of
these publications were read to find out whether inclu-
sion criteria were met. Also, we screened reference lists
of all relevant articles for other relevant studies. We con-
tacted the authors if an article did not provide enough
information to adequately assess inclusion criteria.
The main characteristics of the included publications
were extracted by two authors (SM and SAML) using
standardized forms.
Quality assessment
A difference in validity of included studies may affect the
conclusions of a systematic review. Therefore, we assessed
the quality of each study: two reviewers (SM and SAML)
independently scored the quality of the included studies
using a set of criteria. These criteria were a combination
of the quality criteria described by Harden et al. and
Prins et al. [12,13]. Each item was scored a “0” if the cri-
terion was not met or if it was unclear whether the cri-
terion was fulfilled, a “1” was given when that particular
criterion was fulfilled. The sum of these scores indicated
the quality score for each study. Disagreement was
resolved by consensus or by a third reviewer (WHH) in
case of persisting disagreement. The preferred study
design was a prospective cohort study. In our study,
10 quality items and 5 informativity items were scored
(Additional file 1: Appendix 2). The informativity score
was not included in the quality score, as this reflects the
quality of the manuscript rather than the quality of the
study. Studies receiving more than 75% of the quality
points (more than 7 points) were considered studies of
high quality. The quality of database studies was assessed
using the same scoring system, but three items of this
system did not apply to this type of research, thus
restricting the total score of these studies to 7 points and
therefore defining a high quality database study as a
study with more than 5 points.
Data analysis
Most studies in this review were too heterogeneous
in their study design to apply statistical analysis of the
data. We compared the results of the studies included
using the quality score and study design (survey study or
database study).
Results
Selection and quality of studies
No search results were found in the Cochrane Library.
Embase identified a total of 2,614 titles. From MEDLINE
1,520 titles were extracted. PsychInfo revealed 19 articles.
After reviewing title and abstract 31 articles were read
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Screening the reference list of these articles revealed one
additional study meeting the inclusion criteria (Figure 1)
[6,7,14-26].
Study characteristics of the 15 included studies are pre-
sented in Table 1. Three studies were database related,
one study combined questionnaires with database research,
and 11 studies were questionnaire-based. One study com-
prised of an abstract only.
The study population of the questionnaire studies
varied between 48 and 658 physicians. The response
rate varied from 28% to 90%. The database studies
had study populations varying from 94 to 1,647 patients.
One database study only included patients of 75 years
or older.
Quality scores are presented in Tables 1 and 2. Three
survey studies and one database study were of high qual-
ity. On average, 2.8 items (range 0–5) on external validity
















     15 studies included 
Figure 1 Systematic review flow diagram.Referral rate after normal PSA test
As most studies defined a PSA < 4 ng/ml as normal, this
value was chosen to differentiate between a normal and
abnormal PSA test result (Tables 3 and 4). After a normal
PSA test result (PSA < 4, or PSA ≤ 4, or age-specific cut
off values, Table 3) referral was described in 2 studies
[14,23], and varied from 0% reported by GPs to 28.6%
referred by GPs and internists [14,23].
Referral rate after moderately increased PSA (≥ 4 ng/ml)
Three database studies showed a referral rate of 31 to
86% after a PSA ≥ 4 ng/ml (Table 4). More patients were
referred in the USA [14,16,19,21,25] than in Spain [24],
and internists [21] referred more often than GPs [19,22-24].
Seven survey studies described referral in 10.5 to 100% of
the PSA values > 4 ng/ml (Table 4). GPs mentioned refer-
ring more often compared to primary care practitioners
(PCPs) [18-20,22-25]. Non-urologic hospitalists mentioned
referring equally often as PCPs [16,17,21,22,25]. One








17 studies excluded 
Table 1 Characteristics of included studies
Reference
number
Year Country Design Participants Source population and response rate QS
[14] 2006 USA Database GPs & internists 505 patients aged 75 years or older, not previously diagnosed with
prostate cancer who underwent a PSA test between 1998 and 2004
4
[24] 2000 Spain Database GP 94 patients not previously diagnosed with prostate cancer with a PSA ≥ 4
in 1998, selected from the pertinent laboratory
6
[21] 1998 USA Database Internists 1,448 patients not previously diagnosed with prostate cancer who in 1993
underwent a PSA test
5
[23] 2008 UK Database
& survey
GPs Database: 709 patients pre-guideline launch and 1,040 men post-guideline
launch with PSA ≥ 3 ng/ml and ≥ 1 PSA test by GPs
7
(survey)
515 patients pre-guideline launch and 607 post-guideline launch with
normal test-result (< 3) (random 25% sample of normal PSA tests by GP)
Questionnaire: 69 GPs from England and Wales, registered for PSA testing
with the National External Quality Assessment Service, 48 responded,
response rate 70%
[18] 2008 France Survey GPs All 1,339 GPs in Auvergne (France) registered with the Urssaf in 2006, 658
responded, response rate 49,1%
5
[26] 2008 UK Survey GPs 502 PCPs in West Suffolk and Ipswich Hospital area (UK), 192 responded,
response rate 38%
6
[7] 2005 Denmark Survey GPs 325 GPs in Northern Denmark (23% woman), 291 responded, response
rate 90%
8
[6] 2003 Ireland Survey GPs 400 GPs from Northern Ireland randomly selected by computer, 282
responded, response rate 71%
6
[15]* 2002 UK Survey GPs 200 GPs registered in the East Surrey region, 118 responded, response rate
59%
2
[19] 1995 USA Survey GPs All 149 OAFP GPs from the Oklahoma City area and 151 randomly selected
OAFP physicians outside this area, 152 responded, response rate 53%
9
[22] 1995 UK Survey GPs/general
surgeons/
geriatricians/FHSA
500 GPs, associated with the Western General Infirmary in Edinburgh,
Scotland, 118 responded, response rate 23,6%
4
373 general surgeons, 85 responded, response rate 22,8%
712 geriatricians, 160 responded, response rate 22,5%
115 FHSAs, 58 responded, response rate 50,4% (and 320 urologists, results
excluded from this SR)
[17] 2007 Japan Survey Internists/general
surgeons (PCP)
935 PCPs (internist and general surgeons not in hospital and no urologist)
in South metropolitan Tokyo, 281 responded, mean response rate 30%
(varying per question)
5
[16] 1998 USA Survey GPs/internists (PCP) All physicians from the AMARP, listing themselves in general internal
medicine, family medicine (or urology, results excluded in this SR). 444
PCPs responded, response rate 51%
6
[20] 1996 USA Survey GPs/internists (PCP) 1.816 PCPs randomly selected from all Arizona-licensed physicians from
the BMESA who selfreported to be GP, family practitioner or internist. 68
were subsequently excluded (various reasons) and 57 were unreachable.
Overall, 141 eligible physicians completed the survey, response rate 42,9%
10
[25] 1996 USA Survey Internists/medical
subspecialists (PCP)
All PCPs in Brooklyn, New York with the MSSNY, 311 PCPs responded,
response rate 28%, including 134 GPs (43,1%) and 177 internists/medical
subspecialists (56,9%)
4
Table order according to study design (database or survey studies), participants (starting with GPs) and year of publication (starting with most recent publications)
Abbreviations: QS Quality Score; PCP Primary Care Physician; GP General Practitioner; OAFP Oklahoma Academy of Family Physicians; SR Systematic Review; FHSA
Family Health Service Advisor; AMARP American Medical Association Registry of Physicians; BMESA Board of Medical Examiners of the State of Arizona; MSSNY
Medical Society of the State of New York.
* abstract only.
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Table 2 Quality scores of included studies
Reference number Year External validity Internal validity Informativity Disagree
a b c d e sum f g h i j sum k l m n o sum
Questionnaire studies
[23] 2008 0 1 1 0 1 3 1 0 1 1 1 4 1 1 1 1 1 5 d,f,h
[18] 2008 0 0 0 1 1 2 1 0 1 1 0 3 1 1 1 1 1 5 g
[26] 2008 1 1 0 1 0 3 1 0 0 1 1 3 1 1 1 0 0 3 n
[17] 2007 1 1 0 0 0 2 1 1 0 1 0 3 1 1 1 0 0 3 d,n
[7] 2005 1 1 1 1 0 4 1 1 0 1 1 4 1 1 1 1 1 5
[6] 2003 0 1 1 1 0 3 1 0 0 1 1 3 0 1 1 1 1 4
[15] i 2002 0 0 0 0 0 0 1 0 0 0 1 2 0 1 1 0 0 2 d,k
[16] 1998 1 1 0 1 0 3 1 1 0 1 0 3 1 1 1 1 1 5
[20] 1996 1 1 1 1 1 5 1 1 1 1 1 5 0 1 1 1 1 4 i
[25] 1996 0 1 0 0 0 1 1 1 0 1 0 3 0 1 1 1 1 4 d
[19] 1995 1 1 1 1 1 5 1 0 1 1 1 4 0 1 1 1 1 4 l,o
[22] 1995 0 0 0 1 0 1 1 0 0 1 1 3 1 1 0 1 1 4 i,m
Database studies ii
[14] 2006 1 1 - 0 1 3 0 - - 1 0 1 1 1 1 1 1 5 d
[24] 2000 1 1 - 1 1 4 0 - - 1 1 2 0 1 1 1 1 4
[21] 1998 1 1 - 0 1 3 0 - - 1 1 2 1 1 1 1 1 5
i Abstract only.
ii Categories c, g and h did not apply to database studies (−).
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other studies [22]. This was also the only study describing
high percentage of follow-up for non-urologic hospitalists.
Referral rate after clearly increased PSA (> 10 ng/ml)
One survey reported that 93% of the physicians (GPs)
referred at PSA > 10 ng/ml [19]. However, three
other surveys mentioned that only 13%, 28% and 20%Table 3 Follow-up after normal PSA values
Reference number Country Cut off (ng/ml)
Database studies
[14] USA PSA < 4
[21] USA PSA < 4
Survey studies
[23] UK PSA < 3
PSA 0.1-4
[18] France NS





[17] Japan PSA ≤ 4
Abbreviations: NS Not Specified; GP General Practitioner; FHSA Family Health Serviceof the physicians (GPs/PCPs) respectively referred at
PSA > 10 ng/ml [15,17,20].
Reported referral rates in the USA were 33% in 1995
(GPs), 60% and 86% in 1998 (PCPs, internists and GPs
respectively, Table 3) [16,19], and 52% in 2006 (GPs)
[14,21]. In the UK, referral rates were 86% and 30% in
1995 and 2008, respectively (all GPs) [22,23]. Cut off












Table 4 Follow-up after abnormal PSA values
Reference number Country PSA Cut off (ng/ml) Referral (%) Repeat test (%) No action (%) PSA > 10 referral (%)
Database studies
[14] USA PSA ≥ 4 51.9 48
Age-specific cut off: 58 42
6.5 (≥ 75 yr)
[24] Spain PSA ≥ 4 31 69
[21] USA PSA ≥ 4 86 56.1 100
Survey studies
[23] UK PSA ≥ 3 18.2 15.7 67 82.7
PSA ≥ 4 30
Mean (calculated) 28.6 71.4
50–59 yr: 6.2
70–84 yr: 13
[18] France NS 10.5






[7] Denmark mean 5 (calculated)
[6] Ireland median 5.4 (calculated) 55
[15]* UK NS 28
[19] USA NS 33 93





[17] Japan PSA > 4 73 20





≥ 80 years: 45
[20] USA NS Most doctors refer with PSA 4-10 13
[25] USA PSA > 4 67.8
Abbreviations: yr year; NS Not Specified; GP General Practitioner; FHSA Family Health Service Advisor.
* abstract only.
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70–84 years old (Table 4) [6,7,23,26].
Repeat testing after normal PSA (< 4 ng/ml)
Repeat testing varied greatly also. One UK survey showed
a high repeat rate reported by all physicians [22], while aFrench survey reported that 72.5% of the physicians
(GPs) took further action after a normal PSA result [18].
Also, in a US survey, 29% of the PCPs reported advising
yearly screening for prostate cancer, even in patients older
than 80 years, with GPs advising this more often than
internists/medical subspecialists (55.6% vs 13.3%) [25].
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PSA (≥ 4 ng/ml)
Only one database study from the USA described that
in 56% of the cases requested by internists an abnormal
PSA value was repeated, while 86% were referred [21].
Repeat testing was also described in two European
studies, but reported cut-off values differed. One survey
study defined PSA ≥ 3 ng/ml as abnormal (15.7% repeat
testing by GPs) and the second survey study reported a
median cut-off of 5.4 ng/ml (55% repeat testing by GPs)
[6,23].
Reasons for repeating and time frame for follow-up
No reasons for referral or repeat testing after an initially
normal PSA value were described in the studies included.
Only one survey described the reasons physicians
had for not referring after a primary elevated PSA value;
the PSA value was considered too low in 70.5% (all
< 10 ng/ml), comorbidity too high in 3.6% and other
reasons in 4.2% [23]. No time frame for conducting
follow-up was reported.
Discussion
This is the first systematic review of the literature focus-
ing on follow-up policy after a normal or elevated PSA
test by GPs and non-urologic hospitalists. Only 15 stud-
ies were published on this topic, most of which were of
low quality. Furthermore, a large variety of opinions and
policies used by general practitioners and non-urologic
hospitalists were described on follow-up after a normal
or an abnormal PSA test result. Only four studies
researched cut-off values for referral or repeat testing.
Reasons for repeating a PSA test after an initial normal
result were not described (although two studies described
testing PSA yearly). Only one study mentioned the rea-
sons for not referring patients after an abnormal PSA
test. A time frame for repeating a test was mentioned in
none of the studies. Therefore, the strongest conclusion
of this systematic review is that there is a large variety in
follow-up after primary PSA testing.
Selection of studies and quality assessment
We conducted this systematic review according to the
proposed guidelines [27]. We believe that our search
strategy was adequate, because we used broad search
terms and only one additional study was included after
checking the reference lists of the included studies.
A limitation of this study is the small number of studies
that was found and the exclusion of one Japanese study
due to language restrictions.
We have arbitrarily chosen a cut-off value of 75% for
the definition of high quality studies. We could not apply
quality scores in further analyses, due to the wide varietyof PSA testing policies and the few data this generated.
Therefore, we refrained from pooling the data and per-
forming meta-analyses.
The interpretation of our results may be limited to the
differences in study design. Database studies may describe
follow-up policies more accurately than survey studies do,
as the latter may include socially acceptable answers
instead of describing the physicians’ true actions. The
number of studies included was too small to uncover
this - expected - effect of study design on the results.
Referral after normal PSA test
After a normal PSA test around 7-10% of the patients
are referred to a urologist in all physician groups.
Referral after an initially normal PSA value seems to
have decreased over time, described by database studies
in the USA [14,21] and survey studies in UK [22,23].
A possible explanation for this finding is that patients
may be referred for other reasons than the PSA value,
for instance because of the presence of therapy resistant
LUTS.
Referral after moderately abnormal PSA test
(PSA ≥ 4 ng/ml)
Non-urologic hospitalists appeared to refer more patients
after an abnormal PSA test than GPs, but seem to refer
about as often as PCPs. Only one study described follow-
up by non-urologic hospitalists, but this study also showed
quite high referral rates for GPs [22].
More patients were referred in the USA [14,16,19,21,25]
than in Spain [24]. These differences between countries
may reflect differences in local guidelines. Until 2009 the
AUA guideline on PSA testing recommended PSA testing
for patients 50 years or older with a life expectancy of
10 years or more [28], while the EAU guideline does not
recommend such screening behavior [29].
In the USA, referral rates differed over time (1995–
1998) [14,16,19,21], which could not be explained by a
change in guidelines, but might be explained by the dif-
ferent designs of these four studies.
In the included survey studies a small group of about
20% of physicians report only referring after a PSA value
> 10 ng/ml [15,17,20]. All guidelines advise to follow-up
an elevated PSA value, but do not mention how or
when follow-up after an abnormal PSA test should be
conducted.
Only one study mentioned the reasons for not referring
after an abnormal PSA test. The main reason was that
the PSA value was considered too low, but comorbidity
also played a role. Another reason might be that the in-
terpretation and further management of abnormal test
results are strongly affected by the physicians' estimation
of pretest disease probability [30]. It is not mentioned if
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ing follow-up testing physicians seem to imply that an
abnormal PSA value holds no consequences for these
patients. Maybe these PSA tests could have been omitted,
because knowing your PSA value to be elevated, can cause
a lot of (unnecessary) distress in patients [31].
Repeat testing after normal PSA test
Repeat PSA testing after a normal PSA test varied greatly.
It seemed to be widely used in the USA (as recommended
by the AUA guidelines) as well as in the UK [22,25], and
to a lesser extent also in France [18], which is not in
accordance with the EAU guidelines. At least two studies
(one UK, one USA) reported that physicians agree with
screening by an annual PSA test [22,25], which is not in
accordance with the European guidelines.
All of the studies included and all of the reported
guidelines were published before the recent presentation
of the ERSPC and the publication of the results of the
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial. Before the publication of the ERSPC and
PLCO results there was no clear evidence on the effect of
PSA testing. This resulted in different opinions and con-
secutively different guidelines on PSA testing, not only
between but also within countries. The ERSPC showed
that PSA-based screening may reduce prostate cancer
mortality by 20%, but it remained unclear which patients
may benefit from screening [3]. However, the PLCO trial
did not show a mortality reduction [32]. Also, a recent
meta-analyses on the effect of population based screen-
ing showed no significant effect on mortality [33]. We
believe that these studies are important to take into ac-
count when considering PSA testing in men who request
this. Recently, the US Preventive Services Task Force
postulated a negative advice on PSA testing [34].
In survey studies, participants may provide desirable
answers, which are not in line with their daily practice.
We have found no study to support this suggestion.
Conclusions
Our study shows that follow-up after a normal or
raised PSA test by GPs and non-urologic hospitalists var-
ies greatly and seems not to be in accordance with prac-
tice guidelines. This could mean suboptimal treatment
for some patients and possibly unnecessary distress in
others. Further research is necessary to assess the reasons
for this follow-up policy.
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